Pure Global
NCT06124287

MRE Predictors of Disease Relapse After Stopping Biologics

MR Enterography Predictors of Disease Relapse After Stopping Biologic Therapy in Crohn's Disease (METEOR).
University College, London·ClinicalTrials.gov·diagnostic testNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Crohn's Disease
Drug/Device/Intervention
MR Enterography (MRE)
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
University College, London
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Feb 01, 2027
Enrollment
150 participants
Primary outcome

To develop and internally evaluate a multivariable prediction model for early disease relapse in patients stopping biological therapy

Summary

This study aims to investigate if MR Enterography (MRE) improves the ability to predict which
 Crohn's disease patients will relapse quickly (disease comes back) after stopping biologic
 medication. MRE is a safe MRI scan of the bowel, widely used in Crohn's disease patients.

ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease [regional enteritis]Crohn disease of small intestine
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06124287
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06124287 through Pure Global AI's free database. This phase not specified trial is sponsored by University College, London and is currently Not yet recruiting. The study focuses on Crohn's Disease. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.